Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Ney Carter Borges: Effectiveness and Safety of Andexanet alfa in Life-Threatening Factor Xa Inhibitor-Associated Bleeding
Ney Carter Borges/LinkedIn
Apr 8, 2026, 14:33

Ney Carter Borges: Effectiveness and Safety of Andexanet alfa in Life-Threatening Factor Xa Inhibitor-Associated Bleeding

Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn about a recent article by Kei Sakamoto et al. published in JACC Asia:

“In this real-world postmarketing surveillance study evaluated the use of andexanet alfa, a specific reversal agent for factor Xa inhibitors (FXaIs), in patients presenting with life-threatening or uncontrolled bleeding.

A total of 365 Japanese patients were included, with a median age of 80 years, representing a high-risk, elderly population frequently encountered in clinical practice.

Bleeding profile

The majority of cases involved intracranial hemorrhage (71.5%), followed by gastrointestinal bleeding, highlighting the severity of presentations treated with andexanet alfa.

Effectiveness

  • 80.9% of patients achieved ‘effective’ or ‘excellent’ hemostasis
  • 30-day survival rate: 83.5% (95% CI: 77.4%–88.0%)

These findings demonstrate robust hemostatic efficacy in a critically ill population

Safety profile

  • Adverse drug reactions: 17.5%
  • Thrombotic events: 8.8% (notably cerebral infarction)
  • Rebleeding events: 1.4%

Notably, more than half of adverse events occurred within the first 72 hours, emphasizing the need for close early monitoring.

Clinical interpretation

Andexanet alfa provides rapid reversal of anticoagulation, enabling effective bleeding control.

However, the associated prothrombotic risk requires careful patient selection and thoughtful timing of anticoagulation resumption.

Conclusion

Andexanet alfa is a clinically effective and essential therapeutic option for FXaI-associated major bleeding, with an acceptable safety profile when used under strict monitoring in high-risk patients.”

Title: Andexanet Alfa for Life-Threatening Bleeding Following Factor Xa Inhibitor Treatment: Postmarketing Surveillance Study in Japan

Authors: Kei Sakamoto, Miyo Ishihara, Hiroko Kato, Hyosung Kim, Masaki Okuda, Shunsuke Hiroki, Masatoshi Koga, Kazunori Toyoda

Read the Full Article on JACC Asia

Ney Carter Borges: Effectiveness and Safety of Andexanet alfa in Life-Threatening Factor Xa Inhibitor-Associated Bleeding

More posts featuring Ney Carter Borges on Hemostasis Today.

and Kazunori Toyoda Andexanet Alfa bleeding disorders Health Hematology Hemostasis Hemostasis News Hemostasis Today Hiroko Kato Hyosung Kim Intracranial Hemorrhage JACC Asia Kei Sakamoto Masaki Okuda Masatoshi Koga Medicine Miyo Ishihara Ney Carter Borges Shunsuke Hiroki
NewsFeed